The HIV pandemic has seen a dramatic increase in tuberculosis (TB) rates amongst 71 pregnant women(1). Maternal TB, regardless of HIV status, is associated with a high 72 incidence of low birth weight (LBW; < 2500 grams) and prematurity (gestational age < 73 38 weeks) in infants(2-4). In South Africa, with its high burden of both TB and HIV, 74 recent advances in neonatal care have improved infant survival, resulting in a 75 considerable group of small and premature TB-exposed newborns requiring preventive 76 therapy against TB. Isoniazid (INH) is the most widely recommended agent for 77
preventing TB disease in children(5). Following Mycobacterium tuberculosis (M.tb) 78
infection, up to 50% infants (< 12 months) will progress to TB disease in the absence of 79 INH preventive therapy (IPT)(6), while post-exposure IPT reduces the risk of TB disease 80 by 60-65%(7). There are limited pharmacokinetic data on INH in young children and 81 none in newborns or LBW infants requiring IPT due to maternal TB. INH is primarily 82 metabolized through acetylation in the liver and intestines, and the acetylation rate 83 genetically determined(8). Developmental and physiological changes in the volume of 84 distribution, maturity of liver enzymes, and the role of acetylation capacity may influence 85 INH dosage requirements in this vulnerable population(9, 10). The aim of this study was 86 to determine the pharmacokinetics of routinely administered INH at 10 mg/kg/day in TB-87 exposed LBW infants. The World Health Organization (WHO) recommends a dosage 88 range of 10 to 15 mg/kg daily. We also describe the influence of N-acetyltransferase 2 89 on the day prior to study drug administration). The INH powder was dissolved in 1-2 ml 136 of sterile water, administered through a nasogastric tube and flushed with 1 ml of water. The following pharmacokinetic parameters were generated using fixed sampling times 163 for each patient through noncompartmental analysis (NCA): C max (the maximum drug 164 concentration observed), T max (the time after drug administration to reach C max ), the 165 AUC 2-5 (area under the time concentration curve from 2-5 hours), t1/2 (the plasma half-166 life), and the k e (elimination constant). The AUC was calculated according to the linear 167 trapezoidal rule. Pharmacokinetic parameters were summarized using medians and 168 interquartile ranges (IQR), except for T max , which was summarized using means and 169 standard deviations (SD). Pharmacokinetic parameters were compared by NAT2 170 genotype, birth weight, weight at the time of pharmacokinetic sampling, gestational age, 171 age at sampling, gender, HIV exposure and feeding type. All covariates were analyzed 172 dichotomously except for NAT2, which was analyzed categorically into three levels: FF 173 (fast), FS (intermediate) and SS (slow) acetylator types. Since sample sizes were small, 174 dichotomous covariates were analyzed using the Wilcoxon rank sum test. NAT2 was 175 analyzed using the Kruskal Wallis test and, if statistically significant, the trend test was 176 used to assess for trend across ordered NAT2 groups. Dichotomous confounders, weight 177 at pharmacokinetic sampling and feeding type were assessed using the Fisher's Exact 178 test. Any p-value <0.05 was considered statistically significant. All data was analyzed 179 remained high (a 2-hour value of 4.6 μg/ml, and a 5-hour value of 4.9 μg/ml, 197 respectively). The t 1/2 ranged from 1.45 to 14.25 hours. Infants below 1750 grams on the day of pharmacokinetic sampling had a higher C max and 213 AUC 2-5 compared to heavier infants (7.66 μg/ml vs. 5.03 μg/ml; p=0.030 and 21.26 214 μg.h/ml vs. 13.19 μg.h/ml; p=0.044, respectively). Figure 3 suggesting increased INH 215 absorption and reduced clearance in smaller infants. Similar findings were observed in 216 infants with lower gestational age; however, these differences were not statistically 217 significant. Feeding also affected C max and AUC 2-5 ; exclusively breastfed infants had a 218 higher C max and AUC 2-5 compared to formula fed infants (7.66 μg/ml vs. 4.94 μg/ml; 219 p=0.003 and 21.26 μg.h/ml vs. 12.03 μg.h/ml; p=0.014, respectively). Since weight at 220 pharmacokinetic sampling was associated with feeding status (p=0.001), feeding and 221 weight were likely confounded; smaller babies being more likely to receive breast milk. 222
Gender did not influence pharmacokinetic parameters. 223 224 ALT levels were determined in 19 (95%) infants at baseline, in 14 (70%) at 3 months, 225 and in 11 (55%) at 6 months. Two 3-month values were abnormal; 1 was mildly elevated 226 (<2.5 times elevated; DMID grade 1) and one moderately elevated (<5 times elevated; 227 DMID grade 2). The mildly elevated value was not repeated, and the moderately elevated 228 infants and adult pharmacokinetic target values were achieved. All but one infant 247 achieved a 2-hour drug plasma concentration of ≥ 3 μg/ml. For the latter, the 2-hour value 248 was 2.9 μg/ml. All infants achieved a 3-hour value of ≥ 1.5 μg/ml. The effect of routine 249 2-3 hourly feeding of LBW-infants did not influence the C max . However, food intake is 250 known to decrease the bioavailability of INH (24) hepatotoxicity may be dose-related (35, 36) . In our study only two ALT results were 300 slightly raised at month 3, with the thrice-elevated value returning to normal at month 301 6.The limited safety data collected was reassuring and no jaundice was observed in any 302 infant. A limitation of the study was the few pharmacokinetic sampling points, mainly 303 because of the small blood volume available in LBW-infants. An earlier time point may 304 have assisted with determining the C max more accurately, as previous pharmacokinetic 305 studies in children indicate that the T max occurs any time between 1 and 2 hours (28, 37) . 306
307
In conclusion, a sound understanding of the pharmacokinetic properties of currently used 308 anti-tuberculosis drugs is essential for optimal use in newborns and infants. LBW-infants 309 receiving 10 mg/kg of INH had desirable drug concentrations, comparable to adult target 310 values. However, a prolonged half-life and reduced elimination of INH was noted in 311 smaller and younger infants, especially in genetically determined slow acetylators. 312 Therefore, we caution against exceeding a dosage of 10 mg/kg in this population. 313
Although no serious adverse effects were observed, more data on safety is needed. 
